SpyGlass Pharma, Inc. Operating Lease, Right-of-Use Asset, Amortization Expense
SpyGlass Pharma, Inc. (SGP) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $125.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-06
- SpyGlass Pharma, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $62.00K, a 38.61% decline year-over-year.
- SpyGlass Pharma, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $63.00K, a 36.36% decline year-over-year.
- SpyGlass Pharma, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-06-30 was $101.00K.
- SpyGlass Pharma, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-03-31 was $99.00K.
- SpyGlass Pharma, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $383.00K, a 5.43% decline from fiscal 2024.
- SpyGlass Pharma, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $405.00K.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|
| 2026-06-30 | $62.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $125.00K 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $63.00K 10-Q · filed 2026-05-14 | ||
| 2025-12-31 | $383.00K 10-K · filed 2026-03-26 | ||
| 2025-06-30 | $101.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $200.00K 10-Q · filed 2026-08-06 | |
| 2025-03-31 | $99.00K 10-Q · filed 2026-05-14 | ||
| 2024-12-31 | $405.00K 10-K · filed 2026-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Beta Bionics, Inc. (BBNX) | United States | $0.979B | -9.66 |
| PROCEPT BioRobotics Corp (PRCT) | United States | $1.001B | -11.77 |
| SI-BONE, Inc. (SIBN) | United States | $0.830B | -49.82 |
| TANDEM DIABETES CARE INC (TNDM) | United States | $1.059B | -16.57 |
| IRADIMED CORP (IRMD) | United States | $1.089B | 52.92 |
| ARTIVION, INC. (AORT) | United States | $1.123B | -345.09 |
| MIMEDX GROUP, INC. (MDXG) | United States | $0.687B | 89.92 |
| ANGIODYNAMICS INC (ANGO) | United States | $0.632B | -13.02 |
| INTEGRA LIFESCIENCES HOLDINGS CORP (IART) | United States | $1.234B | -193.02 |
| ORTHOPEDIATRICS CORP (KIDS) | United States | $0.592B |